Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
about
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en-gb
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@nl
type
label
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en-gb
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@nl
prefLabel
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en-gb
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@nl
P2093
P50
P1154
2-s2.0-85010410295
P1476
Erratum to: Serum IL-33, a new ...... ximab in rheumatoid arthritis.
@en
P2093
Alice Courties
Edward M Vital
Elodie Rivière
Gianfranco Ferracioli
Houria Hendel Chavez
Jérémie Sellam
Paul-Olivier Rouzaire
Xavier Mariette
Yassine Taoufik
P2888
P356
10.1186/S13075-017-1221-4
P5530
P577
2017-01-23T00:00:00Z
P6179
1074193711